Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Breast Cancer Drug Pipeline Report' returned 438 results - Page 1 of 22  FEATURED RESULTS Antibody Drug Target Atlas in Oncology Cancer Diagnostic Testing World Markets Drug Delivery in Cancer - Technologies, Markets and Companies Targeting Protein Kinases for Cancer Therapy Cancer Risk Assessment: Chemical Carcinogenesis, Hazard Eval...   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Drug Delivery in Cancer - Technologies, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 639 of drug delivery in the management of cancers of the brain, the bladder, the breast, the ovaries and the prostate are used as examples to illustrate different approaches both experimental and clinical Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place   Bioseeker, June 2010, Pages: 913 This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses Triple Analysis: Breast Cancer, Lung Cancer and Cancer Vaccines   Bioseeker, July 2011, Pages: 2895 and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast Triple Analysis: Breast Cancer, Colorectal Cancer and Cancer Vaccines   Bioseeker, March 2011, Pages: 2628 comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified Triple Analysis: Breast Cancer, Colorectal Cancer and Lung Cancer   Bioseeker, July 2011, Pages: 3292 for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines   Bioseeker, Oct 2010, Pages: 2182 comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified Triple Analysis: Breast Cancer, Prostate Cancer and Cancer Vaccines   Bioseeker, Oct 2010, Pages: 2410 comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline - 2011   BioPharm Reports (VennBio Ltd.), Feb 2011, Pages: 95 The breast cancer immunotherapy pipeline is showing rapid development. This report presents findings on more than 30 candidate therapies, including 22 therapeutic vaccines and 11 antibodies Triple Analysis: Breast Cancer, Lung Cancer and Pancreatic Cancer   Bioseeker, July 2011, Pages: 2846 for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug Triple Analysis: Breast Cancer, Lung Cancer and Prostate Cancer   Bioseeker, July 2011, Pages: 3074 for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug Triple Analysis: Breast Cancer, Colorectal Cancer and Pancreatic Cancer   Bioseeker, March 2011, Pages: 2579 development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs Triple Analysis: Breast Cancer, Colorectal Cancer and Prostate Cancer   Bioseeker, March 2011, Pages: 2807 development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs Triple Analysis: Breast Cancer, Cancer Vaccines and Antibodies   Bioseeker, Sep 2011, Pages: 3516 I: Breast Cancer The breast cancer report part comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed Triple Analysis: Breast Cancer, Apoptosis and Cancer Vaccines   Bioseeker, Dec 2011, Pages: 3189 comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified Triple Analysis: Breast Cancer, Angiogenesis and Cancer Vaccines   Bioseeker, Jan 2012, Pages: 3276 comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified Triple Analysis: Breast Cancer, Pancreatic Cancer and Prostate Cancer   Bioseeker, May 2010, Pages: 2361 development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs Triple Analysis: Breast Cancer, Lung Cancer and Apoptosis   Bioseeker, Dec 2011, Pages: 3853 and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast Triple Analysis: Breast Cancer, Lung Cancer and Angiogenesis   Bioseeker, Jan 2012, Pages: 3940 and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast Triple Analysis: Breast Cancer, Cancer Vaccines and Peptides   Bioseeker, Nov 2011, Pages: 2478 I: Breast Cancer The breast cancer report part comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed Triple Analysis: Breast Cancer, Lung Cancer and Antibodies   Bioseeker, Sep 2011, Pages: 4180 to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer Results:  First -   Prev -   1 -   2 -   3 -   4 -   5 -   6 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets1    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network